http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#Head http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#assertion http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#provenance http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#pubinfo http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#assertion http://purl.obolibrary.org/obo/DOID_5419 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5419 http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00831 http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association http://www.w3.org/2000/01/rdf-schema#label for the management of schizophrenia trifluoperazine hydrochloride tablets usp are effective for the short term treatment of generalized non psychotic anxiety however trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments i e benzodiazepines when used in the treatment of non psychotic anxiety trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warnings the effectiveness of trifluoperazine hydrochloride tablets as a treatment for non psychotic anxiety was established in a 4 week clinical multicenter study of outpatients with generalized anxiety disorder dsm iii this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non psychotic conditions in which anxiety or signs that mimic anxiety are found i e physical illness organic mental conditions agitated depression character pathologies etc trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00831 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#provenance http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#pubinfo http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#sig http://purl.org/nanopub/x/hasSignature Hv7/gYcmdaPMB5ytP7IHLV1Qip6Tvo05Re7nF1slSSf/qyGZoYk1im3Z29D1Lm99GXovfr1JDIuuwogYjDZTrFlBDjUVUe+iDth5vgrEQHV3c6N3izNRsasTNZSIIxHiD0xM40DGCK3+0XPMuqcZOMYxCKkj+BiI5fccKlNNyI8= http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://purl.org/dc/terms/created 2021-06-14T08:56:34.513+02:00 http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RANucs0eEfrBwqScLQtWOgUQMEJyon8e3cEzIeadpxRoE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs